Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | TGM1 | P22735 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229265 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30229262 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL31379527 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30229034 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30229159 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL22348034 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL26510676 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL696467 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL9241437 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1780742 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024102621-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024064026-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-112752757-B | Tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-107949558-B | Muscarinic agonists | 赫普泰雅治疗有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-09-16 | — | — | US | disclosed |
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-09-16 | — | — | US | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012066077-A1 | 1,4 DI SUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000469-A9 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2000469-A2 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 2551/4885NPC1 1935/4885RAB9A 685/4885 |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | CCR4, CCR1, CCR3 | SMN1; SMN2 3096/4885NPC1 2345/4885RAB9A 2364/4885 |
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | SMN1; SMN2 4719/4885NPC1 4028/4885RAB9A 760/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | SMN1; SMN2 2551/4885NPC1 1935/4885RAB9A 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.